Story perspectives

Sonnet BioTherapeutics Merges with Rorschach to Form HSI

7/14/2025

36 4

Summary

Story summary

Sonnet BioTherapeutics and Rorschach I LLC have merged to create Hyperliquid Strategies Inc. (HSI), focusing on crypto treasury management.
The merger is valued at $888 million, comprising 12.6 million HYPE tokens and over $305 million in cash.
HSI will become the largest U.S.-listed holder of HYPE tokens, enhancing high-throughput trading capabilities.
Bob Diamond will serve as Chairman, and David Schamis as CEO, prioritizing biotech asset development.
Shareholders will receive Contingent Value Rights (CVRs) tied to Sonnet's biotech assets.

1 of 1

Story summary

Sonnet BioTherapeutics and Rorschach I LLC have merged to create Hyperliquid Strategies Inc. (HSI), focusing on crypto treasury management.
The merger is valued at $888 million, comprising 12.6 million HYPE tokens and over $305 million in cash.
HSI will become the largest U.S.-listed holder of HYPE tokens, enhancing high-throughput trading capabilities.
Bob Diamond will serve as Chairman, and David Schamis as CEO, prioritizing biotech asset development.
Shareholders will receive Contingent Value Rights (CVRs) tied to Sonnet's biotech assets.